Niagen Bioscience, Inc.
NAGE
$3.65
-$0.15-3.95%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -6.99% | -0.43% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -6.99% | -0.43% | |||
| Cost of Revenue | -5.25% | 0.64% | |||
| Gross Profit | -7.96% | -1.02% | |||
| SG&A Expenses | -5.43% | 12.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.79% | 6.68% | |||
| Operating Income | -25.06% | -50.35% | |||
| Income Before Tax | 52.24% | -7.83% | |||
| Income Tax Expenses | 42.81% | 31.53% | |||
| Earnings from Continuing Operations | 52.90% | -9.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 52.90% | -9.74% | |||
| EBIT | -25.06% | -50.35% | |||
| EBITDA | -18.90% | -48.05% | |||
| EPS Basic | 51.24% | -8.89% | |||
| Normalized Basic EPS | -20.73% | -48.67% | |||
| EPS Diluted | 38.61% | 1.00% | |||
| Normalized Diluted EPS | -20.44% | -47.69% | |||
| Average Basic Shares Outstanding | 1.20% | -1.01% | |||
| Average Diluted Shares Outstanding | 0.14% | -2.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||